ARTYKUŁ

Maria Jarecka, Piotr Borowicz

Rekombinowane leki biologiczne w terapii reumatoidalnego zapalenia stawów
2009-09-15

Recombinant biological drugs in rheumatoid arthritis. Rheumatoid arthritis (RA) is a chronic, inflammatory disease associated with significant morbidity, deformity and impaired quality of life. The aim of therapy is to inhibit inflammatory process, joint destruction and internal organs involvement. The tumor necrosis factor (TNF)-antagonists infliximab, etanercept and adalimumab are the "first generation" of recombinant biologics approved in the treatment of RA. Characteristics of these biopharmaceuticals, their efficacy and tolerability in rheumatoid arthritis are presented.
Keywords: Infliximab, etanercept, adalimumab. rheumatoid arthritis, therapy.

Rekombinowane leki biologiczne w terapii reumatoidalnego zapalenia stawów

175.06 kB | 21 grudnia 2017